An open randomised trial of second-line endocrine therapy in advanced breast cancer

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1996 • 3,395 citations

Improving the Quality of Reporting of Randomized Controlled Trials

1996 • 2,811 citations

Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 • 1,075 citations

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

2000 • 990 citations

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 • 700 citations

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

1998 • 647 citations

Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

2002 • 572 citations

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

2001 • 567 citations

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

2000 • 531 citations

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

1998 • 421 citations

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1996 • 412 citations

Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification

1986 • 380 citations

Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate

2001 • 360 citations

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

2001 • 300 citations

Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

1998 • 267 citations

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *

1996 • 261 citations

Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

2002 • 254 citations

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.

2001 • 172 citations

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

1998 • 171 citations

Use of aromatase inhibitors in breast carcinoma.

1999 • 169 citations

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

2001 • 94 citations

Endocrine and Clinical Endpoints of Exemestane as Neoadjuvant Therapy

2002 • 70 citations

Lessons from the use of aromatase inhibitors in the neoadjuvant setting.

1999 • 53 citations

Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.

1998 • 41 citations

Stepwise estrogen suppression manipulating the estrostat

2001 • 18 citations

New Endocrine Drugs for Treatment of Advanced Breast Cancer

1990 • 12 citations